The drug is prescribed for the treatment of the following diseases as part of complex therapy: flu and other acute respiratory viral diseases, including against the background of immunodeficiency states; infections caused by the virus Herres simplex, Varicella zooster, Herres simplex genitalis, including in persons with impaired immune system; cytomegalovirus infection in persons with immunodeficiency; radiation immunodeficiency; HIV infection; encephalitis and encephalomyelitis of viral etiology; acute and chronic hepatitis B and C; urethritis, epididymitis, prostatitis, cervicitis and salpingitis of chlamydial etiology; lymphogranuloma venereum; oncological diseases; multiple sclerosis; candidal lesions of the skin and mucous membranes; human papillomavirus infection.
Main active ingredients: 1 ml of solution contains sodium oxodihydroacridinyl acetate 125 mg.
Auxiliary components: sodium citrate; citric acid; water for injections.
Available in the form of a solution for injection.
This drug Overin belongs to the group of immunomodulatory, antineoplastic drugs.
The drug has an antiviral effect against DNA and RNA genomic viruses, is used for therapeutic and prophylactic purposes in viral infections.
The drug has a pronounced anti-Chlamydial effect. The effectiveness of the active component is due to the fact that it increases the concentration of external interferons, especially interferon-α.
The drug potentiates bone marrow stem cells, T-lymphocytes and macrophages. It exhibits an immunomodulatory effect, helps to normalize the balance between subpopulations of T-helper and T-suppressor cells.
In some infections, the drug can lower the production of tumor necrosis factor, activate natural killer cells. The drug activates the system of polymorphonuclear leukocytes.
The highest activity of interferons is achieved several hours after intramuscular injection of the drug and it lasts for 16-20 hours.
The drug is excreted unchanged in the urine.
The drug Overin is prescribed for the treatment of the following diseases as part of complex therapy:
- flu and other acute respiratory viral diseases, including against the background of immunodeficiency states;
- infections caused by the virus Herres simplex, Varicella zooster, Herres simplex genitalis, including in persons with impaired immune system;
- cytomegalovirus infection in persons with immunodeficiency;
- radiation immunodeficiency;
- HIV infection;
- encephalitis and encephalomyelitis of viral etiology;
- acute and chronic hepatitis B and C;
- urethritis, epididymitis, prostatitis, cervicitis and salpingitis of chlamydial etiology;
- lymphogranuloma venereum;
- oncological diseases;
- multiple sclerosis;
- candidal lesions of the skin and mucous membranes;
- human papillomavirus infection.
Also, the drug is prescribed for the prevention of influenza and other acute respiratory viral diseases.
The drug in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or to one of the auxiliary components.
The drug is contraindicated for use in autoimmune diseases and renal failure.
The drug is not used in pediatrics.
Application during pregnancy and lactation
This drug is not recommended for pregnant women – only under strict indications determined by the attending physician.
If it is necessary to take the drug during breastfeeding, lactation is suspended.
Method of administration and dosage
The drug Overin is administered to adults intramuscularly at 250 mg or in terms of 4 ̶ 6 mg per kg of body weight. If necessary, a single dose can be increased to 500 mg.
The course of therapy is 5-7 injections at a dose of 250 mg with an interval of 48 hours, the course dose depends on the clinical situation and the nature of the disease. The duration of the course of treatment is 8-12 days.
The prophylactic dose is 250 mg. With long-term use (from 3 to 12 months), the recommended interval between injections of the drug is 3-7 days.
In HIV infection, the drug solution is used in combination with specific antiviral drugs. The course of treatment consists of 10 injections of 250 mg each, with an interval between injections of 48 hours. After the completed course of treatment, take a break for 2 months. It is possible to use repeated courses according to indications.
There is no information on overdose cases.
The drug is usually well tolerated when used in the recommended doses.
Allergy may occur in case of individual intolerance. In particular, it can be observed:
- pain at the injection site;
- low-grade fever,
- allergic reactions (including anaphylactic reactions).
Storage conditions and periods
Expiration date – up to 2 years from the production date indicated on the package. Storage periods should not be exceeded.
Storage temperature should not exceed 25 ° C. Temperature deviations can change the properties of the preparation, therefore it should always be stored in its original packaging.